India · Delayed Price · Currency is INR Mold-Tek Packaging Earnings Call Transcripts
Fiscal Year 2027
-
Record quarterly turnover and all-time high EBITDA per kg were achieved, driven by strong growth in pharma, food, and FMCG, and operational efficiencies from unit consolidation. Paints, food, and pharma segments are expected to sustain double-digit growth, while raw material price volatility and higher working capital remain key risks.
Fiscal Year 2026
-
Strong annual growth was driven by pharma (219% YoY), paints, and FMCG, with improved EBITDA margins from operational consolidation. FY 2027 guidance targets 13–15% value growth, INR 1,000 crore sales, and INR 210 crore EBITDA, with expansion funded by internal accruals.
-
EBITDA and PAT grew 20% year-over-year, with strong performance in paints, F&F, and pharma segments. Operational efficiencies, new product MoUs, and reduced CapEx are set to drive future growth, while capacity utilization and margins are expected to improve.
-
Q2 saw 9.65% sales growth and 8.37% EBITDA growth year-over-year, with strong momentum in pharma packaging and Food & FMCG segments. Paints and lubricants were impacted by heavy rains, but double-digit growth is expected in Q4 as demand recovers.
-
Revenue grew 22% year-over-year with EBITDA margin at 19.7% and net profit up 35%. Pharma and food/FMCG segments drove growth, while paints remained strong and lubricants lagged. Capacity expansions and new product lines are set to support continued double-digit growth.
Fiscal Year 2025
-
Sales grew 11.8% and EBITDA rose 7% year-over-year, while net profit declined 9% due to higher costs. Pharma division broke even and is set for rapid growth, with strong momentum in food, FMCG, and paint segments. CapEx focus remains on pharma and printing.
-
Q3 FY25 saw strong sales and EBITDA growth, but PAT declined due to higher depreciation and interest. Pharma segment is scaling rapidly, with capacity expansion and new product launches expected to drive double-digit growth next year, especially as paint and FMCG segments stabilize.
-
Sales volumes grew 7.2% in H1 and 7% in Q2 year-over-year, with EBITDA up 4.5% in Q2. Profit declined 10% due to higher depreciation and interest from recent CapEx. Pharma and Qpack segments are ramping up, with full-year double-digit growth and INR 38/kg EBITDA targeted.
-
Q1 FY25 saw 7.5% YoY and 9.07% QoQ volume growth, with EBITDA up 2.77% YoY but per kg EBITDA down due to new plant ramp-up costs. Pharma and ABG segments are expected to drive growth in H2, supporting a 15% volume growth target for FY25.